

PREVAIL™

Paclitaxel Coated PTCA Balloon Catheter

Understand why the Medtronic paclitaxel coated PTCA balloon is an effective treatment option for in-stent restenosis, de novo lesions, and small vessels.

[DOWNLOAD BROCHURE](#)




[Indications, Safety, and Warnings](#)


OVERVIEW

**RIGHT CASE
RIGHT TIME
PREVAIL™**

Watch an animation to see why Prevail™ drug-coated balloon offers the performance you want for treating complex lesions during percutaneous coronary interventions.¹



percutaneous coronary interventions.¹



PRODUCT DETAILS

DEVICE PERFORMANCE Superior deliverability – deliberately designed to maximize pushability. ² VIEW PERFORMANCE	DRUG COATING Rapid absorption of paclitaxel facilitated by biocompatible urea excipient. ^{1,3} SEE DRUG COATING	CLINICAL EVIDENCE Excellent safety and efficacy as demonstrated in the IN.PACT™ Falcon Clinical Program and confirmed in the PREVAIL™ VIEW DATA	ORDERING INFORMATION Broad range of sizes to give you more options for treating vessels. SEE SIZES
--------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------

DEVICE PERFORMANCE

SUPERIOR DELIVERABILITY²

PowerTrac™ technology and hydrophilic coating enable superior deliverability

1. Ultra-slim balloon material for optimised folds
2. Low profile marker bands
3. Tapered tip
4. Lower crossing profile²
5. PowerTrac™ technology and hydrophilic coating
6. Compatible with 5 F guide catheter



PREVAIL™ DCB IS TWICE AS PUSHABLE AS IN.PACT™ FALCON DCB†

PUSHABILITY

DRUG COATING

PROVEN FREEPAC COATING⁵

FreePac coating combines two proven components that work together:

- **Paclitaxel** – potent antirestenotic drug that remains within tissue throughout the healing process⁶
- **Urea** – biocompatible excipient that enables rapid and reliable drug transfer within 30-60 seconds^{1,3}

CLINICAL EVIDENCE

BUILDING CLINICAL EVIDENCE

The PREVAIL™ Study adds to the clinical legacy of the IN.PACT™ Falcon Clinical Program.

IN.PACT™ FALCON CLINICAL PROGRAM

- IN.PACT™ Falcon DCB with FreePac coating[‡]
- 10 trials
- > 1,400 patients

EXCELLENT RESULTS WITH PREVAIL™ STUDY^{‡5}

- Includes complex lesions
- 54.7% ISR
- 75% small vessel in de novo lesions

VERY LOW LATE LOSS IN ALL PATIENTS AT 6 MONTHS⁴

Maximum acceptance rate 0.5 mm

0% STENT THROMBOSIS, TV-HI, OR CARDIAC DEATH FOR ALL PATIENTS⁴

ORDERING INFORMATION

Balloon Diameter (mm)	Balloon Length (mm)				
	10	15	20	25	30
2.0	PRV020010RX	PRV020015RX	PRV020020RX	PRV020025RX	PRV020030RX
2.25	PRV022510RX	PRV022515RX	PRV022520RX	PRV022525RX	—
2.50	PRV025010RX	PRV025015RX	PRV025020RX	PRV025025RX	PRV025030RX
2.75	PRV027510RX	PRV027515RX	PRV027520RX	PRV027525RX	—
3.0	PRV030010RX	PRV030015RX	PRV030020RX	PRV030025RX	PRV030030RX
3.5	PRV035010RX	PRV035015RX	PRV035020RX	PRV035025RX	PRV035030RX
4.0	PRV040010RX	PRV040015RX	PRV040020RX	PRV040025RX	PRV040030RX

DOWNLOADS

[Prevail™ Launch Brochure \(.pdf\)](#)
1.3MB

[Ordering Information Sheet \(.pdf\)](#)
202KB

ADDITIONAL RESOURCES

RELATED PAGES

- Telescope™ Guide Extension Catheter

REQUEST MORE INFORMATION

[CONTACT US](#)

*™Third-party brands are trademarks of their respective owners.
 † 99% improved push force compared to IN.PACT™ Falcon DCB.
 ‡ IN.PACT™ Falcon DCB and Prevail™ DCB use the same FreePac™ coating. PREVAIL Study did not have powered endpoints.

REFERENCES

- 1 Prevail Instructions for Use.
- 2 Compared with IN.PACT Falcon DCB, SeQuent® Please NEO DCB*, Agent™ DCB, and MagicTouch™ DCB. Deliverability defined as pushability. Based on bench test data, 2020. Bench test data may not be indicative of clinical performance.
- 3 Barnett BJ. Contrast nephrotoxicity. *J Am Soc Nephrol.* August 1994;5(2):125-37.
- 4 Latib A, et al. PREVAIL Study 12-month results. Results presented at PCR 2020.
- 5 Virmani R. Arterial wall response to drug-coated balloons. *Confluence.* September 2016;13:15-19.
- 6 Creemers B, Clever Y, Schaffner S, et al. Treatment of coronary in-stent restenosis with a novel paclitaxel urea coated balloon. *Minerva Cardioangiol.* October 2010;58(5):583-8.